RxDoctor Payments Data

Kent Fung, MD

Family Medicine · Brick, NJNPI 1730347212

Payments from drug & device makers

$12,509in general payments, 2019–2025

Across 859 payments — averaging $14.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Novo Nordisk$2K
  • GSK$1K
  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$908
  • Pfizer$752
  • plus $4K from 34 others

What the payments were for

  • Speaking & faculty fees$600%
  • Food & beverage$12,449100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,509 in reported general payments places this provider in the 95th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$145,535
Medicare patients
396
Services billed
1,576

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol147$138,994
JardianceEmpagliflozin90$117,058
OzempicSemaglutide63$106,596
RybelsusSemaglutide31$73,874
Trelegy ElliptaFluticasone/Umeclidin/Vilanter72$45,305
JanuviaSitagliptin Phosphate27$39,602
JanumetSitagliptin Phos/Metformin Hcl26$32,663
EliquisApixaban30$31,588
MounjaroTirzepatide25$29,527
XareltoRivaroxaban16$25,964
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$22,589
Xigduo XrDapaglifloz Propaned/Metformin12$19,729
TrulicityDulaglutide15$16,429
Janumet XrSitagliptin Phos/Metformin Hcl11$13,415
Tresiba Flextouch U-100Insulin Degludec15$12,082

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,080$180,47094 claims
AstraZenecaFarxiga, Breztri Aerosphere$2,641$161,583176 claims
Boehringer IngelheimJardiance, Tradjenta$651$128,964103 claims
MerckJanuvia, Janumet, Janumet Xr$292$85,68064 claims
Lilly USA, LLCMounjaro, Trulicity$637$45,95640 claims
GSKTrelegy Ellipta$1,165$45,30572 claims
PfizerEliquis$752$31,58830 claims
Johnson & JohnsonXarelto$184$25,96416 claims
AbbVieSynthroid$1,090$1,40835 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Brick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →